Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tumor necrosis factor ligand superfamily member 15 (TNFSF15), commonly known as tumor necrosis factor-like ligand 1A (TL1A), is a proinflammatory cytokine belonging to the tumor necrosis factor (TNF) superfamily. It exists in both membrane-bound and soluble forms and is primarily expressed by endothelial cells, macrophages, dendritic cells, and activated lymphocytes in response to inflammatory stimuli. TL1A acts as a ligand that binds to death receptor 3 (DR3) on effector T cells, innate lymphoid cells, and fibroblasts, initiating downstream NF-κB and MAPK signaling pathways. This interaction co-stimulates T-cell activation, enhances the production of proinflammatory cytokines (such as IFN-γ, IL-17, and IL-22), and promotes tissue remodeling and collagen deposition.
Dysregulation and overexpression of TL1A are strongly implicated in the pathogenesis of chronic inflammatory and autoimmune diseases, most notably inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, as well as rheumatoid arthritis, psoriasis, and systemic sclerosis. Genetic polymorphisms in the TNFSF15 gene are highly correlated with susceptibility to and severity of IBD. Consequently, TL1A has emerged as a major therapeutic target, with several monoclonal antibodies—such as tulisokibart, afimkibart, and duvakitug—undergoing clinical development. These therapeutic agents neutralize TL1A to block the TL1A-DR3 signaling axis, thereby simultaneously suppressing mucosal inflammation and halting or reversing tissue fibrosis, offering a novel dual-action approach to treating refractory autoimmune disorders.
Monoclonal antibody-mediated neutralization of soluble and membrane-bound TL1A, preventing its binding to death receptor 3 (DR3) and decoy receptor 3 (DcR3), thereby inhibiting downstream NF-κB and MAPK signaling pathways to suppress inflammation and fibrosis.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tumor necrosis factor ligand superfamily member 15 (TNFSF15).